Symlin

Patients meeting any of the following criteria should not be considered for symlin therapy: poor compliance with current insulin regimen; poor compliance with prescribed self-blood glucose monitoring; have an hba1c 9%; recurrent severe hypoglycemia requiring assistance during the past 6 months; presence of hypoglycemia unawareness; confirmed diagnosis of gastroparesis; require the use of drugs that stimulate gastrointestinal motility; pediatric patients.

Malar eminence, and a large laceration of the tongue. Shortly after admission, the patient suddenly developed spiking fevers. Blood cultures were positive for Streptococcus viridans, and IV penicillin was administered. Approximately 9 days later, leg paresis occurred. A review of the chest radiographs revealed the presence of a paraspinal mass and gas in the sixth thoracic vertebral body Fig. 3A.
Response. Although the observation of temporal progression for improvement in the theoretical predictive value systolic velocity criteria for arterial incompetence, greater effect was observed in the accuracy of color sonography for the diagnosis of venous incompetence. the injection of papavenine in many patients, the. Signed december 22, 2006 effective december 22, 2007 amends the us food drug and cosmetic act strengthen fda's medwatch system for adverse event reporting mandatory for manufacturers or distributors to report serious adverse events to fda in 15-days serious adverse event: a ; results in i ; death; ii ; a life-threatening experience; iii ; in-patient hospitalization; iv ; a persistent or significant disability or incapacity; or v ; a congenital anomaly or birth defect; or b ; requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described under subparagraph a.
In september 1998, the company entered into an agreement with ortho-biotech, inc and a drug manufacturer for the assignment of the rights and obligations of ortho-biotech to purchase quantities of bulk symlin from this manufacturer under a july 1997 agreement among the company, ortho-biotech and the manufacturer. Law Department Block Grant funds -- Federal Home Program funds -- Housing Rehabilitation Program -- CDBG Year XXII O 619-96 ; 969 Block Grant funds -- expenses of the Code Enforcement -- Demolition Program CDBG Year XXII O 621-96 ; 969 Contract Jacobson mower parts O 643-96 ; 988 Contract commercial gases -- not to exceed two years O 644-96 ; 988 Contract fasteners -- not to exceed two years O 645-96 ; 969 Contract janitorial supplies O 639-96 ; 987 Contract long distance telephone service -- City exchanges and concession -- coin operated telephones -- three years -- Division of Information System O 646-96 ; 969 Contract of lumber O 640-96 ; 987 Contract of office furniture O 713-96 ; 966 Contract of paint -- paint materials O 642-96 ; 988 Contract one collator -- with attachments -- Printing and Reproduction Division O 637-96 ; 987 Contract rental and laundry services -- work clothing O 638-96 ; 987 Contract standard wire -- not to exceed -- two years O 636-96 ; 986 Contract typewriter maintenance -- repair service O 641-96 ; 988 Contract with DAC Services -- provide employee background and criminal checks O 711-96 ; 969 Federation for Community Planning -- fiscal agent -- Summer Sprout Program O 701-96 ; 969 One electric scissor lift -- Division of Water O 712-96 ; 966 Re-extend -- retirement date -- Lieutenant Michael O'Malley -- one year -- beginning June 30, 1996 O 765-96 ; 967 and symmetrel.
References 1. 2. 3. Holst, J. J. 1997 ; Annu Rev Physiol 59, 257-271. Drucker, D. J. 1998 ; Diabetes 47, 159-169. Thorens, B. 1992 ; Proc Natl Acad Sci U S A 89, 8641-8645. Thorens, B., Porret, A., Buhler, L., Deng, S. P., Morel, P., and Widmann, C. 1993 ; Diabetes 42, 1678-1682. Dillon, J. S., Tanizawa, Y., Wheeler, M. B., Leng, X. H., Ligon, B. B., Rabin, D. U., Yoo-Warren, H., Permutt, M. A., and Boyd, A. E. 1993 ; Endocrinology 133, 1907-1910. Graziano, M. P., Hey, P. J., Borkowski, D., Chicchi, G. G., and Strader, C. D. 1993 ; Biochem Biophys Res Commun 196, 141-146. Ulrich, C. D., Holtmann, M., and Miller, L. J. 1998 ; Gastroenterology 114, 382397. Frimurer, T. M., and Bywater, R. P. 1999 ; Proteins 35, 375-386. Horn, F., Weare, J., Beukers, M. W., Horsch, S., Bairoch, A., Chen, W., Edvardsen, O., Campagne, F., and Vriend, G. 1998 ; Nucleic Acids Res 26, 275279. Fehmann, H. C., Gke, R., and Gke, B. 1995 ; Endocr Rev 16, 390-410. Flint, A., Raben, A., Astrup, A., and Holst, J. J. 1998 ; J Clin Invest 101, 515-520. Gutzwiller, J. P., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., and Beglinger, C. 1999 ; Gut 44, 81-86. Kieffer, T. J., and Habener, J. F. 1999 ; Endocr Rev 20, 876-913. Gutniak, M., Orskov, C., Holst, J. J., Ahren, B., and Efendic, S. 1992 ; N Engl J Med 326, 1316-1322. Ahren, B. 1998 ; Bioessays 20, 642-651. Holst, J. J. 1999 ; Curr Med Chem 6, 1005-1017. Wheeler, M. B., Lu, M., Dillon, J. S., Leng, X. H., Chen, C., and Boyd, A. E., 3rd. 1993 ; Endocrinology 133, 57-62. Lankat-Buttgereit, B., Gke, R., Fehmann, H. C., Richter, G., and Gke, B. 1994 ; Exp Clin Endocrinol 102, 341-347. Beinborn, M., Lee, Y. M., McBride, E. W., Quinn, S. M., and Kopin, A. S. 1993 ; Nature 362, 348-350. Kopin, A. S., Lee, Y. M., McBride, E. W., Miller, L. J., Lu, M., Lin, H. Y., Kolakowski, L. F., and Beinborn, M. 1992 ; Proc Natl Acad Sci U S A 89, 36053609. Flentke, G. R., Munoz, E., Huber, B. T., Plaut, A. G., Kettner, C. A., and Bachovchin, W. W. 1991 ; Proc Natl Acad Sci U.S.A. 88, 1556-1559. Gke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., and Gke, B. 1993 ; J Biol Chem 268, 19650-19655. Liaw, C. W., Grigoriadis, D. E., Lorang, M. T., De Souza, E. B., and Maki, R. A. 1997 ; Mol Endocrinol 11, 2048-2053. Cascieri, M. A., Fong, T. M., and Strader, C. D. 1995 ; J Pharmacol Toxicol Methods 33, 179-185. Schwartz, T. W., Gether, U., Schambye, H. T., and Hjorth, S. A. 1995 ; Current Pharmaceutical Design 1, 325-342. Ing the vast potential \vealth of the calth, Noel-Baker: mankind \r.oulcl enter a 15-onderful new age What makes Inc most optililistic is the of econoniic prosperity and of peace and pre; in~ble to the tcst ban treaty and the friendship bet\veen nations. speeches of the late President Kennedy and And finally again Father Pire: fornler Premicr Khrushcl~evlllade about it. If the atoni bonib should fall tomorrow Dr. King: on the world, it w i l because you quarThe greatest hopc for world peace today reled with your neighbor today. may well be the realization on t l epart of These above quotations arc bold, brilzcn, people all over the nrorld and the leaders wicked statements you say? . Protestant b of the nations of the world that war is futile. In short, tl~eremust be a peacef~d Refomled Young People I an1 sure we all agrec to that fact. We cannot look, work, coexistence or thcrC will be coanoihilation. or pray for peace here on earth you say? \tihat eviclence is there to sho\v that rero ligion has evcr been or in the f i ~ Surely- we agree wit11 that. The desire and prayer for earthly peace is not in I~nnnony be effective in promoting pc * ncr and good with the will of God. IVe kno\v I-hal the will anlong men? purpose of God is to bring about IIis kingDr. King: dom in thy way of wars and nutlors of bvar. All the grc at rc.ligions of the o.orlc1 have For thus saitl~the Lord to His people in always sougllt to promote peace and good llatt. 24: 4-8: "And Jesus answerc: d and will among n1r.n. In Uieir ethical systems said unto them, Take heed that no Inan love is always the center. The centrill mesdeceive yon. For many shall c o ~ eill my sage has always been peace and good will anlong men. But sad it is, thiit too miiny name, saying. I an1 Cluist; and shall deceive many. And ye shall hear of wars axid ruadherents of a particular faith have only mors of war: see that ye be not troubled: crcctb for religion and follow not Chis pattern for a wall; of life. for all these things must come to pass, but If brotlierhoocl is to become a rcality, re- the end is not yet. For nation sllall rise against nation, and kingdom against kingtllicli of ligion lilust someho\v get into t l ~ the battle and influcncc the lni~ldsof mcn dom: and thcrc shall 11e fanlines, ancl pestiancl women to be t eto h e i ethical in- lences, rind earthquakes in diverse places. MI thess things are the beginning of sorsights. nut I aln sure t11; tt if t11e religions of the world Lire to bring about peace they ro\vs." must rise to Lhc level of not figllting anlong It is evident that all these things must themselves. There is a need for inclividual come to pass before the conling of the Lord religions to realize that God has revealed in Glory. When we, therefore, desire thnt Hilliself through : ill religions ancl that there God's kingdom s l l come then \vc 1111lst in should weds pray for \Tars and runlors of \trars to is solnc t n ~ dl. Ancl no roligio~~ pern~ititself to b r arrogant that it fails come to pass, because \ye h o \ that Christ's Ungdom is coming only through this way. to see that Goc1 has not leit IIi~nselfwithout Certainly there is no difficulty in seeiug a witness. even tl~oughil may be in another the folly of praying or desirinfi peace from religion. Noel-Baker : wir and dcstnlction. From little on wc have Tlir influence of the b t c Pope Jolin, of heard honl the pulpit, from catechism, in Pope Paul, anil of the Protr: stant leaders the school, and in the home that a chili1 of sho\.s ho\v i111port: lnt it is in bringing naGod does not pray and cannot pray for tions to acccpt the ideas iuncl policies on earthly peace. which peace clepencls. But is this the cnd? Do \ve just say these And further comments: five Kobe1 Peace Prize \.inners are \i7rong Angcll: because they do not understand that you Tliere can be no ptmnar~r: rrt pcacc, no cannot pray for earthly peace? save security against uuclear annihilalio~~, KO! There is niore wrong tlliul thc mcrc by the creation of a morkable world governincapability to pray for peacc or1 earth. 'I'l~e ment. h~ndamcntalevil of these men's tl~eoriesis Bovd Orr: havthnt no one call pray for peacc witl~out If governments, instead of collaborath~gfor ing peace in his o\vn heart. 'There is only war, would hegill to collaborate in developone kind of peace and that is the peace and synagis.

Benefited from a significant decline in our effective tax rate, partly as a result of a change in accounting standards, but also due to settlements of certain tax audits and changes in the mix of income earned in various countries. These financial factors had a relatively large impact on our earnings in 2002, but are not expected to be as important, in a relative sense, to earnings growth going forward. Balanced sales growth from new products, market growth and share gains, combined with operational leverage, reduced interest costs, and a lower tax rate pushed net earnings to 6.9 million in 2002, 47.9% ahead of last year. All in all, 2002 was a successful first year for us as a public company and our results bolstered Alcon's financial strength, leaving us with the financial flexibility that is so critical to the continuation of our value creation cycle. Alcon is a new company to many of our shareholders, but we have been building our leadership position in this industry for over half a century. During that time we have learned that our financial success is not just about the next and tace. Complete details: diet pills dietary supplements weight loss supplements fat burners diet programs natural weight loss appetite suppressants cellulite cream bmi body mass index ; calculator site directory symlin symlin perhaps not enough may be said about the famous, or rather infamous, low-carb craze.

The usual recommended treatment with symlin in persons with type 1 diabetes is 15 mcg, which may be increased up to 60 mcg; and in persons with type 2 diabetes is 60 mcg, which may be increased to 120 mcg and tacrine. Members of the RADAR group developed the OLINDA EXM software, with its technical basis previously established in the literature 1 ; . Vanderbilt University continues distribution of the code since receiving FDA approval through a 510 K ; mechanism in 2004. An update of the code, including new decay data and realistic standardized. I started on symlin about six months ago and it is like a magic injection for me and tamiflu. To determine the approximate m.w. of the released chemotactic activity in the supernatant fluids harvested at 72 h response to 10 g bleomycin, molecular sieve column chromatography was performed using Sephadex G-200 Pharmacia, Piscataway, NJ ; . At a flow rate of 6 ml h, HLF culture supernatant fluid was eluted with PBS, and fractions after the void volume were evaluated for NCA and MCA in duplicate.

6.3: KRS 218A.170-218A.994 - MISC. PROVISIONS - PENALTIES b ; Sell that which is not required to be destroyed by law and which is not harmful to the public. The proceeds shall be paid into the fund created in KRS 218A.435. Any sale shall be a public sale advertised pursuant to KRS Chapter 424. KRS 218A.425 Valuation of property retained for official use When seized property is retained for official use by law enforcement agencies under this chapter the value of the property shall be determined as follows: 1 ; Vehicles shall be valued at their tax value; 2 ; All other property shall be valued at its fair cash value by the property valuation administrator; 3 ; Property shall be valued as of the time of sale by the law enforcement agency. DRUG PARAPHERNALIA KRS 218A.500 Definitions for KRS 218A.500 and 218A.510 Unlawful practices Penalties As used in this section and KRS 218A.510: 1 ; "Drug paraphernalia" means all equipment, products and materials of any kind which are used, intended for use, or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling, or otherwise introducing into the human body a controlled substance in violation of this chapter. It includes, but is not limited to: a ; Kits used, intended for use, or designed for use in planting, propagating, cultivating, growing, or harvesting of any species of plant which is a controlled substance or from which a controlled substance can be derived; b ; Kits used, intended for use, or designed for use in manufacturing, compounding, converting, producing, processing, or preparing controlled substances; c ; Isomerization devices used, intended for use, or designed for use in increasing the potency of any species of plant which is a controlled substance; d ; Testing equipment used, intended for use, or designed for use in identifying, or in analyzing the strength, effectiveness or purity of controlled substances; e ; Scales and balances used, intended for use, or designed for use in weighing or measuring controlled substances; f ; Diluents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose and lactose, used, intended for use, or designed for use in cutting controlled substances; g ; Separation gins and sifters used, intended for use, or designed for use in removing twigs and seeds from, or in otherwise cleaning or refining marijuana; h ; Blenders, bowls, containers, spoons, and mixing devices used, intended for use, or designed for use in compounding controlled substances; i ; Capsules, balloons, envelopes, and other containers used, intended for use, or designed for use in packaging small quantities of controlled substances; j ; Containers and other objects used, intended for use, or designed for use in storing or concealing controlled substances; k ; Hypodermic syringes, needles, and other objects used, intended for use, or designed for use in parenterally injecting controlled substances into the human body; 6.3.11 Rev. 6 2005 and tao. Cancer cells. MIA PaCa-2 . ; , BxPC-3 5, dotted line ; , and PANC-1 cells E ; were treated with increasing concentrations of parthenolide for 48 h. Cell growth was determined with the 2, -tetrazolium-5-carboxanilide inner salt colorimetric proliferation assay and expressed relative to control-treated cells 100% ; . Points, average from at least three independent experiments set up in duplicate; bars, FSD. * , P 0.05 versus control-treated cells.

Sensory conduction velocity evoked by tactile stimulation to the tip of a digit and recorded via near nerve electrodes is a reliable and sensitive conduction test of the most distal nerve part. However, near nerve recordings are not tolerated very well by most patients, and therefore, the aim of the study was to find a non-invasive, sensitive technique able to detect early alteration of sensory conduction velocity. Nerve conduction studies of the median and ulnar nerves, recorded at the wrist and evoked by tactile stimulation of digits III and V, were performed in 31 diabetic patients. Furthermore the median, ulnar, peroneal and sural nerves were studied using conventional conduction techniques. All patients mean age 45.7 years ; were diagnosed within one year, clinically asymptomatic, with normal neurological and autonomic evaluations. Results were compared with those of a group of 72 controls mean age 43.1 years ; . Sensory conduction study was pathologic in 57% of the patients using electrical stimulation, and in 75% of the patients using tactile stimulation. Surface recording from the median and ulnar nerve of responses to tactile stimulation at the tip of Digits III and V is a non-invasive, well tolerated technique that increases the diagnostic yield in diabetic patients with distal neuropathy and tarceva.

Managed through a joint venture with Merck & Co., Inc. Sold by Schering-Plough outside the U.S. only 3 Also sold in Japan through a separate comarketing agreement with Bayer and targretin and symlin. Cally in those starting or about to start a health activity. Their environment in life, work, and home differs and their lifestyle and sense of values regarding life also differ. Therefore, advice or assistance deemed pertinent by the supporter may be interpreted as criticism, slander or even contempt depending on sensitivity or physical and psychological conditions of those receiving such advice, etc., and may invite the result contrary to original purposes. The quality of mutual relationship between the party behaving and those assisting can be an extremely important key.14, 15 ; 4-1. Level of changes Behavioral science captures changes occurring to humans at four levels. They are changes in knowledge, changes in attitude, changes in behavior, and changes in group behavior or organizational behavior.16 ; Figure 2 shows the time required for these changes to occur without pressure or submission and the relative difficulties. As shown, changes in knowledge occur most easily, followed by changes in attitude. Factors constituting attitude are different from those of knowledge in that emotional factors such as positiveness or negativeness are included. On the other hand, changes in behavior entail more difficulty and time compared to these two changes. Changes in group or organizational behavior are most difficult and time-consuming among these four changes. 4-2. Behavior Behavior is basically preceded by an objective. In other words, our behavior is motivated by a desire to achieve an objective. However, rationale for behavior is not necessarily clear in conscience. Freud is one of those who first recognized the importance of subconscious motive. According to him, motive is defined as a desire inherent in an individual, a sense of psychological dissatisfaction, drive or impulse. On one hand, an objective exists outside an individual. Objectives are described as "desirable" compensations that direct the motive, and psychologists.

Pramlintide acetate symlin ; is a relatively new adjunct treatment for diabetes both type 1 and 2 ; experimental agents many other potential drugs are currently in investigation by pharmaceutical companies and tarka. We have been engaged in the pharmaceuticals business for over 130 years. Our founder, Ernst Schering, established a pharmacy in Berlin, Germany, in 1851, and on October 23, 1871, formed our predecessor company under the name "Chemische Fabrik auf Actien vorm. E. Schering ; ". During the course and in the aftermath of World War II, substantially all of Schering AG's subsidiaries, patents, trademarks and other properties located outside of Germany were liquidated, confiscated or expropriated. Following the entry of the United States in World War II, the United States government confiscated the assets of German companies in the United States, including Schering AG's subsidiary Schering Corporation. This subsidiary was operated by a guardian appointed by the United States government for the next decade and, in 1952, was divested by the United States government to an investment group. Following a merger, the company became known as Schering-Plough Corporation in 1971. Schering AG and ScheringPlough Corporation have been totally independent of each other for many years, and have an agreement relating to the use of the name "Schering". See " Patents and Other Intellectual Property" for a description of this agreement. Schering AG operates its pharmaceutical business in the United States and Canada under the Berlex trade name. The Schering AG Group significantly restructured its operations over the past decade to concentrate on its pharmaceutical business. We also have expanded our pharmaceutical product portfolio and obtained promising new technologies through a number of small- to mid-sized acquisitions and licensing as well as research and development collaboration relationships. For a description of certain of our more significant licensing and collaboration relationships, see " Products" and " Research and Development Collaboration Efforts.

Strategy Subtype Capitation deductions Pharmacies, out-of-group providers, home health providers Implement therapeutic guidelines for authorizations Use existing utilization management UM ; system Establish office procedures for internal SAI authorization Definition of Strategy Subtype Determine amount health plan deducts from medical capitation payment for SAIs Determine amount physician group pays pharmacies, out-of-group providers, and home health providers through direct billing to claims department * Utilize evidence-based guidelines for SAI prescribing e.g., multiple sclerosis and rheumatoid arthritis ; Adapt existing UM system to process requests for SAI authorizations Establish processes physicians and staff follow to obtain authorization from the physician group's UM department for SAIs that are the physician group's financial responsibility Hire personnel in claims UM department to implement and manage SAI authorization program Determine price paid for each SAI using HMO capitation deductions Develop network s ; of local pharmacies or contract with a pharmacy vendor to supply SAIs at a lower price Negotiate lower SAI price with local pharmacy by physician group ; Negotiate lower SAI price by redirecting patients to the selected home health provider by physician group ; Negotiate a lower price with SAI manufacturer directly by physician group ; Establish process by which pharmacies, out-of-group providers, and or home health providers bill and receive reimbursement from the physician group directly for SAIs Establish a system to monitor each individual SAI cost through internal claims processing system Establish a system to monitor overall SAI costs through internal claims processing system Monitor compliance with internal prior-authorization process and guidelines for SAIs by individual or department within physician group ; Review medical services capitation deductions related to SAIs for verification of patient eligibility, duplicate or over-charges for medications, and correct interpretation of contracted financial responsibility Review outpatient pharmacy, out-of-group providers, and home health bills related to SAIs for verification of patient eligibility, duplicate or over-charges for medications, and correct interpretation of contracted financial responsibility Verify patient's insurance coverage by UM department in the physician group before SAI authorized ; Transfer risk for SAI costs to HMO shared risk or no risk for physician group ; Number of Physician Groups Adopting the Strategy 2 3, 1.
We expect to incur substantial operating losses for at least the next two years due to ongoing expenses associated with the continuation and potential expansion of our research and development programs, including the clinical development of symlin, exenatide, exenatide lar, ac2592 and ac3056, preparation for the planned commercialization of symlin and related general and administrative support.

Substitutions associated with ZDV, 3TC, or IDV resistance are shown from baseline pre ; and at the time of LN biopsy post ; from each of six subjects EJ ; from whom both ``pre'' and ``post'' sequences were obtainable. The baseline data are derived from sequencing of plasma, and the post-treatment data are derived from both plasma and LN samples. There was general agreement of sequences from plasma and LN. Where a discrepancy was noted, a substitution is shown when it occurred in one of the two compartments. Substitutions seen in post-treatment samples not present at baseline are shown in boldface. Numbers in data columns correspond to codon number of either the RT or protease. Amino acid designations follow International Union of Pure and Applied Chemistry single-letter code. A substitution for which a clear association with resistance is unknown is shown in parenthesis. * Occurring in a subject not on IDV ; as a natural polymorphism. Mutation seen in LN DNA but not in LN RNA or plasma of subject G. Working group on Headache associated with infection: A. Pradalier, France; D. Russell, Norway; Fumihiko Sakai, Japan Chairman N. Suzuki, Japan; K. M. A. Welch, U.S.A. Advisors: E. Schmutzhard, Austria, JR Weber, Germany. As an organization accredited for continuing medical education, the american psychiatric association designates this cme activity as meeting the criteria for up to 10 credit hours in category i of the physician's recognition award of the ama and of the cme requirements of the apa, provided it is used and completed as designed.

It has been postulated that for any structure to be deemed a cause of back pain, the structure should have been shown to be a source of pain in patients, using diagnostic techniques of known reliability and validity 224 ; . The diagnostic blockade of a structure with a nerve supply with the ability to generate pain can be performed to test the hypothesis that the target structure is a source of a patient's pain. Evidencebased interventional diagnostic techniques include facet joint blocks, discography, sacroiliac joint injections, and transforaminal epidurals or selective nerve root blocks. Fritton, J. C., Rubin, C. T., Qin, Y. X., and McLeod, K. J. 1997 ; Whole-body vibration in the skeleton: development of a resonance-based testing device. Ann. Biomed. Engin. 25, 831 839 Erben, R. G. 1997 ; Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J. Histochem. Cytochem. 45, 307313 Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R. 1987 ; Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595 610 Turner, R. T. 2000 ; Invited review: what do we know about the effects of spaceflight on bone? J. Cell. Physiol. 89, 840 847 Dehority, W., Halloran, B. P., Bikle, D. D., Curren, T., Kostenuik, P. J., Wronski, T. J., Shen, Y., Rabkin, B., Bouraoui, A., and Morey-Holton, E. 1999 ; Bone and hormonal changes induced by skeletal unloading in the mature male rat. Am. J. Physiol. 276, E62E69 Gross, T. S., and Rubin, C. T. 1995 ; Uniformity of resorptive bone loss induced by disuse. J. Orthop. Res. 13, 708 714 Rubin, C. T., and Lanyon, L. E. 1985 ; Regulation of bone mass by mechanical strain magnitude. Calcif. Tissue Int. 37, 411 417 O'Connor, J. A., Lanyon, L. E., and MacFie, H. 1982 ; The influence of strain rate on adaptive bone remodelling. J. Biomech. 15, 767781 Fyhrie, D. P., and Carter, D. R. 1986 ; A unifying principle relating stress to trabecular bone morphology. J. Orthop. Res. 4, 304 317 Gross, T. S., Edwards, J. L., McLeod, K. J., and Rubin, C. T. 1997 ; Strain gradients correlate with sites of periosteal bone formation. J. Bone Miner. Res. 12, 982988 Baldwin, K. M., White, T. P., Arnaud, S. B., Edgerton, V. R., Kraemer, W. J., Kram, R., Raab-Cullen, D., and Snow, C. M. 1996 ; Musculoskeletal adaptations to weightlessness and development of effective countermeasures. Med. Sci. Sports Exerc. 28, 12471253 Desplanches, D., Mayet, M. H., Ilyina-Kakueva, E. I., Sempore, B., and Flandrois, R. 1990 ; Skeletal muscle adaptation in rats flown on Cosmos 1667. J. Cell. Physiol. 68, 48 52 Received for publication March 7, 2001. Revised for publication June 1, 2001. Symlin online Summary comparison of national plans and practices This presentation is based on information collected thanks to a specific questionnaire elaborated by the EMEA and collected by Dr. Sgolne Aym for the Rare Disease Task Force, and from a survey performed by the NEPHIRD project, supported by the Public Health Programme of DG Health and Consumer Protection, and coordinated by Dr. Domenica Taruscio. The comparison of national initiatives was possible for some but not all member states: Belgium, Denmark, Estonia, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. No standardised definition of Rarity Where the EU Regulation 141 2000 on Orphan Drugs defines a rare disease using the epidemiological threshold of 5 10 000, some member states use different thresholds: 1 10 000 in Sweden, 1 50 000 in the United Kingdom.